Parents will soon have access to Owlet’s Dream Sock with medically-certified CE-Marking across the European marketsLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”…
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab…
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in…
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31,…
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of…
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseasesMOUNTAIN VIEW, Calif.,…
AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its…
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral…
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a…
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing…